Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

  • Medical Education & Research
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma
+ More Topics

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL

    September 2019

    Kim HT, et al., Clin Cancer Res – Researchers have developed a prognostic model for patients with chronic lymphocytic leukemia (CLL) on the probable outcomes of undergoing reduced-intensity hema-topoietic cell transplantation (HCT).

    The model incorporates disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT, plus cytogenetic assessments of del(17p) and karotypic abnormalities to stratify patients into four risk groups. 

     

    Read More

  • New Prognostic System for Patients with Relapsed Follicular Lymphoma

    May 2018
    Sureda A, et al. Cancer – A large-scale, long-term study of patients with relapsed follicular lymphoma (FL) has identified a new prognostic scoring system to assess risks of allogeneic hematopoietic cell transplantation (HCT). Results have shown that HCT can lead to a 5-year overall survival (OS) of 61% and a progression-free survival of 52%.

    Read More

  • Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT

    May 2018
    Peggs KS and Moscowitz CH. Blood Advances – In a Point-Counterpoint feature in Blood Advances, two prominent hematologists, Drs. Karl S. Peggs and Craig H. Moscowitz, debate “Should all patients with Hodgkin lymphoma who relapse after autologous HCT be considered for allogeneic HCT?”

    Read More

  • Study Compares 5-Year Outcomes of Auto- vs. Allo-HCT in Patients with High-Risk FL

    May 2018
    Smith SM, et al. Cancer – Patients with high-risk follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, can achieve a 5-year OS of 70% after autologous HCT.

    Read More

  • Study Shows Age Doesn't Affect Survival in HCT for NHL

    April 2018
    Shah NN, et al. Blood Advances – Results from a study of 1,629 older adults show that older age per se should not make a patient ineligible for an allogeneic hematopoietic cell transplant (HCT) in non-Hodgkin lymphoma (NHL).

    Read More

  • Auto-HCT Improves Survival in Patients with FL and Early Therapy Failure

    February 2018
    Casulo C, et al. Biol Blood Marrow Transplant – Patients with follicular lymphoma (FL) experiencing therapy failure within 2 years of frontline chemotherapy had better outcomes with an autologous HCT (auto-HCT) compared to a matched cohort of patients who did not undergo auto-HCT.

    Read More

  • Long-Term Outcomes Show Effectiveness of Reduced-Intensity HCT in MCL

    February 2018
    Robinson SP, et al. Bone Marrow Transplant – Patients with mantle cell lymphoma (MCL) who have relapsed after an autologous transplant generally have a poor prognosis. Further treatment options include a second autologous transplant, an allogeneic transplant, or various alternative treatment strategies including novel agents.

    Read More

  • New Clinical Recommendations on the Role of HCT in Mature T Cell and NK/T Cell Lymphomas

    December 2017
    Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant – New recommendations on the role of hematopoietic cell transplantation (HCT) for mature T cell and natural killer (NK)/T cell lymphomas outline clinical practice algorithms for 14 histological subtypes.

    Read More

  • Maintenance with Rituximab Prolongs Survival after Auto-HCT for Mantle Cell Lymphoma

    November 2017
    Le Gouill S, et al. N Engl J Med – Rituximab maintenance therapy after autologous hematopoietic cell transplantation (HCT) significantly prolonged event-free survival, progression-free survival, and overall survival in patients with mantle cell lymphoma, according to a phase III randomized study of 299 patients <66 years old.

    Read More

  • Recent HCT Survival Improvements Reported for Hodgkin Lymphoma

    June 2017
     Hegerova L, et al. Bone Marrow Transplant – This study of 72 patients with relapsed/refractory Hodgkin lymphoma (HL) has shown that allogeneic HCT outcomes have improved over time, primarily due to reductions in non-relapse mortality and decreased early relapse.

    Read More

  • Five-Year Disease-Free Survival Greater Than 80% with Auto-HCT for Hodgkin and DLBC Lymphoma

    April 2017
    Myers R, et al. Biol Blood Marrow Transplant –In this multi-center study of 1,617 patients who survived for at least two years following autologous hematopoietic cell transplantation (auto-HCT) for Hodgkin lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL), 5-year disease-free survival (DFS) was >80%.

    Read More

  • Early Auto-HCT Improves Survival in High-Risk FL Patients

    April 2017
    Casulo C, et al. Biol Blood Marrow Transplant – Patients with follicular lymphoma (FL) experiencing therapy failure within 2 years of frontline rituximab-based therapy have better outcomes when they undergo autologous hematopoietic cell transplantation (HCT) early (≤1 year from therapy failure), according to research results presented at the BMT Tandem Meetings.

    Read More

  • Report: Long-Term Follow Up Needed after HCT for CLL

    January 2017
    van Gelder M, et al. Bone Marrow Transplant – Although allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for patients with chronic lymphocytic leukemia (CLL), a new study shows that HCT results in a higher mortality rate in transplant recipients compared to an age-, sex- and calendar year-matched general population.

    Read More

  • ASBMT Report: The Role of Allogeneic Transplant for CLL

    November 2016
    Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant – Although allogeneic hematopoietic cell transplantation (HCT) is currently relegated to later stages of relapsed or refractory chronic lymphocytic leukemia (CLL), novel targeted therapies have altered clinical decision-making for the disease.

    Read More

  • MRD Accurately Predicts Survival in Patients with CLL

    October 2016
    Kovacs G, et al. J Clin Oncol – Minimal residual disease (MRD) quantification results in improved progression-free survival (PFS) prediction in patients who achieve partial response (PR) and those who achieve complete remission (CR) after completion of chemotherapy or immunotherapy to treat chronic lymphocytic leukemia (CLL), according to combined results from two phase III studies.

    Read More

  • Haploidentical and Matched Related Donor HCT Result in Comparable Outcomes

    June 2016
    Ghosh N, et al. J Clin Oncol – In this multi-center study of 987 adults with lymphoma undergoing HCT with post-transplant cyclophosphamide, outcomes were comparable between haploidentical (n=180) and matched sibling donors (MSD; n=807).

    Read More

  • HCT Yields Over 80% 3-Year Survival and Low Relapse in High-Risk FL Patients

    May 2016
    Laport GG, et al. Biol Blood Marrow Transplant – Hematopoietic cell transplantation (HCT) using reduced-intensity conditioning with rituximab yields excellent survival in high-risk patients with follicular lymphoma (FL), according to results of a prospective phase II study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

    Read More

  • Review: Advances in Allo-HCT Expand Use in Older Patients with NHL

    May 2016
    Fenske TS, et al. Biol Blood Marrow Transplant – In this review, the authors present data supporting allogeneic HCT as a therapeutic option for patients with non-Hodgkin lymphoma (NHL) diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma focusing on patients over age 60.

    Read More

  • Prognostic Model Predicts HCT Outcomes in Patients with DLBCL

    April 2016
    Fenske TS, et al. Br J Haematol – Researchers have developed a prognostic model to identify which patients with diffuse large B-cell lymphoma (DLBCL) who have failed a prior autologous transplant would best benefit from a subsequent allogeneic transplant.

    Read More

  • Haploidentical, Unrelated Donor HCT Outcomes Comparable in Lymphoma

    March 2016
    Kanate AS, et al. Blood – Reduced-intensity HCT using haploidentical or matched unrelated donors (URD) yields comparable outcomes, according to a study of 917 adults transplanted for lymphoma.

    Read More

  • Allo- Better than Auto-HCT for Early Relapsed or Refractory Follicular Lymphoma

    March 2016
    Lunning MA, et al. Brit J Haematol – An analysis of 44 patients with early relapsed or refractory follicular lymphoma (FL) shows a significant difference in 3-year event-free survival (EFS) between allogeneic and autologous transplantation (80% vs. 42%, respectively; p<0.015), but only in patients with previous remission duration of ≤12 months.

    Read More

  • Meta-Analysis: Outcomes of HCT in Hodgkin Lymphoma Have Improved Over Time

    February 2016
    Rashidi A, et al. Bone Marrow Transplant – This meta-analysis encompassing 1,850 patients with Hodgkin lymphoma (HL) has found that hematopoietic cell transplantation (HCT) outcomes in HL have improved since 2000.

    Read More

  • HCT for Relapsed or Refractory Follicular Lymphoma Leads to 5-Year Survival of 52%

    December 2015
    Sureda A, et al. ASH abstract oral presentation, December 2015 – Patients with relapsed/refractory follicular lymphoma (FL) can experience a 5-year progression-free survival (PFS) of 52%, according to the results of the largest FL study to date of 1,538 allogeneic hematopoietic cell transplant (HCT) recipients whose outcomes were reported to two major transplant registry databases.

    Read More

  • Comparable Outcomes in Unrelated Donor vs. Haploidentical HCT with Cyclophosphamide

    December 2015
    Mussetti A, et al. ASH abstract oral presentation, December 2015 – Lower-intensity hematopoietic cell transplantation (HCT) using haploidentical donors and post-transplant cyclophosphamide for GVHD prophylaxis can achieve outcomes comparable to HLA-matched unrelated donor transplants, according to results of a retrospective study of 917 adults with Hodgkin or Non-Hodgkin lymphoma.

    Read More

  • Prognostic Model Identifies Relapsed DLBCL Patients Who Can Achieve Durable Progression-Free Survival After Allogeneic HCT

    December 2015
    Fenske TS, et al. ASH abstract oral presentation, December 2015 – A new prognostic model identifies a subgroup of adults with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous transplant who can experience long-term progression-free survival following an allogeneic transplant.

    Read More

  • Survival 80% or Higher with Allogeneic HCT after Failed Autologous HCT for Lymphoma

    December 2015
    Rezvani AR, et al. Bone Marrow Transplant – In a study of 47 patients with lymphoma who had failed prior autologous hematopoietic cell transplantation (HCT), 3-year overall survival was 81% after allogeneic HCT with a conditioning regimen using total lymphoid irradiation and antithymocyte globulin (TLI-ATG).

    Read More

  • Survival 65% or Higher in HCT for Progressive or Refractory Follicular Lymphoma

    December 2015
    Yano S, et al. Bone Marrow Transplant – A multi-center retrospective study of reduced-intensity hematopoietic cell transplantation (HCT) in 46 adults with follicular lymphoma has shown that this therapy can result in a 5-year overall survival (OS) of 71.6%.

    Read More

  • Allogeneic HCT Better than Autologous HCT for Progression-Free Survival in Follicular Lymphoma

    September 2015
    Klyuchnikov E, et al. Biol Blood Marrow Transplant – In adults with follicular lymphoma (FL), reduced-intensity allogeneic hematopoietic cell transplantation (HCT) yields better long-term survival compared to autologous HCT, according to results of a study of 518 rituximab-treated patients with FL transplanted between 2000 and 2012.

    Read More

  • Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma

    July 2015
    Graff TM, et al. Bone Marrow Transplant – Researchers comparing outcomes of 230 patients with myeloma or lymphoma who underwent autologous hematopoietic cell transplantation (HCT) on an inpatient vs. outpatient basis within a single transplant program have found comparable outcomes in the two cohorts.

    Read More

  • ASBMT Evidence-Based Review: The Role of HCT in Hodgkin Lymphoma

    May 2015
    Perales M-A, et al. Biol Blood Marrow Transplant — This systematic evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) evaluated the role of hematopoietic cell transplantation (HCT) in the treatment of Hodgkin lymphoma (HL) in pediatric and adult populations.

    Read More

  • PET Scans Predict Relapse in Patients with NHL

    April 2015
    Bachanova V, et al. Oral presentation, BMT Tandem Meetings — New research results from a large-scale study have demonstrated that positron emission tomography (PET) scans can be used to predict risk of relapse in adults undergoing allogeneic HCT for non-Hodgkin lymphoma (NHL).

    Read More

  • Long-Term Outcomes after HCT for Mantle Cell Lymphoma

    April 2015
    Vaughn J, et al. Oral presentation, BMT Tandem Meetings — A study of 70 patients with mantle cell lymphoma (MCL) undergoing non-myeloablative hematopoietic cell transplantation (HCT) demonstrated that a majority can achieve 5-year survival and can discontinue immunosuppressive medications.

    Read More

  • Alternative Donor HCT for Lymphoma Patients Lacking an HLA-Matched Donor

    December 2014
    Bachanova V, et al. Bone Marrow Transplant — Allogeneic HCT using matched unrelated donors, mismatched unrelated donors, and umbilical cord blood (UCB) have comparable survival in patients with lymphoma, according to a large-scale analysis of 1,593 transplants between 2000 and 2010 reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • HIV-1 Infection Shouldn’t Preclude HCT for Lymphoma

    December 2014
    Alvarnas J, et al. ASH abstract oral presentation, December 2014 — One-year overall survival is 86.6% in patients with HIV-associated lymphoma treated with autologous hematopoietic cell transplantation (HCT), according to results from a study conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and presented at ASH.

    Read More

  • Pre-Transplant Conditioning with Rituximab Yields Good Outcomes in Adults with Follicular Lymphoma

    December 2014
    Laport GG, et al. ASH abstract oral presentation, December 2014 — Adding rituximab to a reduced-intensity transplant conditioning regimen in chemotherapy-sensitive patients with follicular lymphoma can result in 2-year overall survival of 83%, according to a multi-center phase II trial of transplants between 2009 and 2012.

    Read More

  • High-Risk CLL: Current Treatment Considerations with Novel Agents and HCT

    October 2014
    Dreger P, et al. Blood — This review examines currently available evidence and theoretical considerations to advise patients with high-risk chronic lymphocytic leukemia (CLL) about the indication and timing of HCT versus the administration of novel classes of drugs such as BCR-signal inhibitors and BCL2 antagonists.

    Read More

  • Specific HLA Alleles Associated with Development of Severe CLL

    October 2014
    Gragert L, et al. Blood — Although CLL has one of the highest familial predispositions of all hematologic malignancies, a strong ethnic predisposition for Caucasians, and a relative sparing of African American and Asian populations, the genetic basis for these differences are not clearly defined.

    Read More

  • Consensus Report: The Role of Autologous and Allogeneic HCT in MCL

    September 2014
    Robinson S, et al. Leukemia — A joint project of the European Group for Blood and Marrow Transplantation (EBMT) and the European Mantle Cell Lymphoma Network (EMCL) has produced a consensus report on the role of autologous and allogeneic HCT in MCL.

    Read More

  • Front-Line Allo- or Auto-HCT Prolongs Survival in Young Patients with PTCL

    September 2014
    Corradini P, et al. Leukemia — This phase II study investigated chemotherapy and HCT in patients with newly diagnosed peripheral T-cell lymphomas (PTCLs) and found that front-line allogeneic or autologous HCT is effective in prolonging disease-free survival (DFS) in young patients (≤60 years).

    Read More

  • Encouraging Progression-Free Survival in HCT for Older NHL Patients

    April 2014
    McClune BL, et al. Biol Blood Marrow Transplant - This CIBMTR study analyzed outcomes of 1,248 patients age ≥40 years undergoing reduced-intensity or non-myeloablative hematopoietic cell transplantation (HCT) for aggressive (n=668) or indolent (n=580) non-Hodgkin lymphoma (NHL).

    Read More

  • Related, Unrelated Donor HCT Comparable in DLBCL

    February 2014
    Avivi I, et al. Bone Marrow Transplant -- A multi-center retrospective analysis of 473 adults with diffuse large B-cell lymphoma (DLBCL) has shown that hematopoietic cell transplantation (HCT) outcomes using matched sibling and unrelated donors are comparable.

    Read More

  • Early Transplant Best in Chemotherapy-Sensitive MCL

    January 2014
    Fenske TS, et al. J Clin Oncol - For patients with chemotherapy-sensitive mantle cell lymphoma (MCL), the optimal timing for either reduced-intensity HCT (RIC-HCT) or autologous HCT (auto-HCT) is early in the disease course, according to a recent study.

    Read More

  • Peri-Transplant Rituximab in Lymphoma Can Lead to Durable Event-Free Survival

    December 2013
    Sauter CS, et al. Biol Blood Marrow Transplant - Non-myeloablative transplantation incorporating peri-transplant-rituximab can lead to a two-year event-free survival (EFS) of 72%, according to results of a prospective trial of 51 patients with CD20+ B-cell non-Hodgkin lymphoma.

    Read More

  • Comparable Outcomes for Unrelated Donor, Cord Blood HCT in Lymphoma

    December 2013
    Bachanova V, et al. ASH abstract oral presentation, December 2013 – A multi-center study of 1,593 adults with non-Hodgkin and Hodgkin lymphoma has found that HLA-matched and one-antigen mismatched unrelated donor transplants and cord blood transplants have comparable outcomes.

    Read More

  • Earlier HCT Improves Outcomes in T-cell NHL

    August 2013
    Smith SM, et al. J Clin Oncol - In patients with T-cell non-Hodgkin lymphoma (NHL) undergoing hematopoietic cell transplantation (HCT), delaying either autologous or allogeneic HCT results in significantly worse outcomes, according to an analysis of 241 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • Review: Allogeneic HCT for Diffuse Large B Cell Lymphoma

    June 2013

    Klyuchnikov E, et al. Bone Marrow Transplant - In this review article, the authors note that despite overall improvements in outcomes of patients with diffuse large B cell lymphoma (DLBCL), approximately 30-40% will develop relapsed or refractory disease.

    Read More

  • Significant Improvement in HCT Survival Over Time

    June 2013

    Hahn T, et al. J Clin Oncol - Survival for patients undergoing allogeneic hematopoietic cell transplantation (HCT) has significantly improved over time, according to a study of 38,060 patients with hematologic malignancies transplanted between 1994 and 2005 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • Autologous, Allogeneic, or Chemotherapy for Transformed Follicular Lymphoma

    April 2013

    Villa D, et al. J Clin Oncol - A multicenter cohort study of 172 patients with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation. Twenty-two patients (13%) underwent allogeneic HCT, 97 (56%) underwent autologous transplant, and 53 (31%) received rituximab-containing chemotherapy.

    Read More

  • No Clinical Benefit in Adding Radioimmunotherapy to BEAM Conditioning in Autologous HCT for Relapsed DLBCL

    March 2013
    Vose JM, et al. J Clin Oncol — In patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (HCT), adding radioimmunotherapy to the standard BEAM conditioning regimen provides no clinical benefit, according to results from a randomized phase III clinical trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

    Read More

  • Graft-Versus-Tumor Effects in Advanced Malignancies

    March 2013

    Storb R, et al. J Clin Oncol - A study of a minimal-intensity pre-transplant conditioning regimen consisting of low-dose total body irradiation with or without fludarabine has shown that it can induce strong graft-versus-tumor (GVT) effects leading to lasting remissions in 45% to 75% of patients.

    Read More

  • HCT for Chemorefractory Mantle Cell Lymphoma

    February 2013
    Hamadani M, et al. Biol Blood Marrow Transplant - This study examined 202 adults with chemotherapy-unresponsive mantle cell lymphoma (MCL) who underwent allogeneic HCT between 1998 and 2010 and whose outcomes were reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • Risk-Stratified Adoptive Cellular Therapy After HCT for CLL

    February 2013
    Richardson SE, et al. Br J Haematol - This study examined outcomes of 50 consecutive patients with chronic lymphocytic leukemia (CLL) transplanted after reduced-intensity conditioning followed by pre-emptive donor lymphocyte infusions (DLI) with the intention of reducing the risk of GVHD.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma